The colonic microbiota and colonic disease

Current Gastroenterology Reports

Volumn 14, Issue 5, 2012, Pages 446-452

  Shanahan, Fergus ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Clostridium difficile; Colon cancer; Inflammatory bowel disease; Irritable bowel syndrome

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTITOXIN; DNA; FIDAXOMICIN; GAMMA INTERFERON; INTERLEUKIN 18; POLYSACCHARIDE; PROBIOTIC AGENT; RIFAXIMIN;

ARTICLE; BACTERIAL COUNT; BIFIDOBACTERIUM LONGUM INFANTIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; COLON DISEASE; COLON FLORA; CROHN DISEASE; CYTOKINE RELEASE; ENTERITIS; FECAL TRANSPLANTATION; HOST PATHOGEN INTERACTION; HUMAN; INCIDENCE; IRRITABLE COLON; MICROBIOME; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; TRANSPLANTATION; ULCERATIVE COLITIS;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLON; COLONIC NEOPLASMS; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; RISK FACTORS;

EID: 84870532596     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0281-5     Document Type: Article

References (72)

1. Sekhirov I, Gill N, Jagova M, et al. Gut microbiota in health and disease. Physiol Rev. 2010;90:859-904.
2. Shanahan F. The gut microbiota in 2011. Translating the microbiota to medicine. Nat Rev Gastroenterol Hepatol. 2011;9:72-4.
3. Clemente JC, Ursell LK, Parfrey LW, et al. The impact of the gut microbiota on human health: An integrative view. Cell. 2012;148:1258-70.
4. Cho I, Blaser MJ. The human microbiome: At the interface of health and disease. Nat Rev Genet. 2012;13:260-70.
5. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18:363-74.
6. Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell. 2010;140:859-70.
7. Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol. 2010;28:623-67.
8. Macpherson AJ, Geuking MB, Slack E, et al. The habitat, double life, citizenship, and forgetfulness of IgA. Immunol Rev. 2012;245:132-46.
9. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA. 2011;108 Suppl 1:4659-65. An excellent overview of the colonic mucus structure and function.
10. Maslowski KM, Vieira AT, Ng A, et al. Regulation of immunomodulatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-6.
11. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469:543-7.
12. Chow J, Lee SM, Shen Y, et al. Host-bacterial symbiosis in health and disease. Adv Immunol. 2010;107:243-74.
13. Marchesi Jr. Human distal microbiome. Environ Microbiol. 2011;13:3088-102.
14. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80.
15. Wu GU, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105-8. An important illustration of the impact of diet on the microbiota.
16. Grenham S, Clarke G, Cryan JF, et al. Brain-gut-microbe communication in health and disease. Front Physiol. 2011;2:94. epub.
17. Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558(Pt 1):263-75.
18. Heijtz RD, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA. 2011;108(7):3047-52.
19. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA. 2011;108:16050-5.
20. Clarke G, Cryan JF, Dinan TG, et al. Review article: Probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther. 2012;35:403-13.
21. Menees SB,Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28-35.
22. Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology. 2011;141:1782-91.
23. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792-801.
24. Jeffery IB, O'Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006.
25. Langhorst J, Junge A, Rueffer A, et al. Elevated human betadefensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104:404-10.
26. Brint EK, MacSharry J, Fanning A, et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011;106:329-36.
27. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: Reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57:1185-91.
28. Hviid A, Svanström H, Frisch M. Antibiotic use in inflammatory bowel diseases in childhood. Gut. 2011;60:49-54.
29. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010;105:2687-92.
30. Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: Relationship to diet, obesity and time in mouse models. Gut. 2010;59:1635-42.
31. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107:14691-6.
32. Shanahan F, Murphy E. The hybrid science of diet, microbes and metabolic health. Am J Clin Nutr. 2011;94(1):1-2.
33. Shoda R, Matsueda K, Yamato S, et al. Epidemiologic analysis of Crohn disease in Japan: Increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63:741-5.
34. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137:1716-24.
35. Muegge BD, Kuczynski J, Knights D, et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science. 2011;332:970-4.
36. Faith JJ, McNulty NP, Rey FE, Gordon JI. Predicting a Human Gut Microbiota's Response to Diet in Gnotobiotic Mice. Science. 2011;333(6038):101- 4.
37. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis. 2012;18(6):1092-100.
38. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228-31.
39. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007;131:33-45.
40. Garrett WS, Gallini CA, Yatsunenko T, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous andmaternally transmitted colitis. Cell Host Microbe. 2010;8:292-300.
41. Bloom SM, Bijanki VN, Nava GM, et al. Commensal bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe. 2011;9:390-403. An important demonstration of the colitogenic potential of the microbiota depending on the host genotype.
42. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141:1135-45. An important series of observations indicating the interplay of multiple factors in determining who gets sick with colitis.
43. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145:1-13. A new finding of the role of the epithelium in discriminating dangerous microbes from harmless commensals.
44. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
45. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology. 2010;139:1816-33.
46. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44.
47. Abubakar I, Myhill D, Aliyu SH, et al. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: A systematic review and meta-analysis. Inflamm Bowel Dis. 2008;14:401-10.
48. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004;127:412-21.
49. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: An assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162-9.
50. Peterson DA, Frank DN, Pace NR, et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 2008;3:417-27.
51. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731-6.
52. Schwiertz A, Jacobi M, Frick J-S, et al. Microbiota in pediatric inflammatory bowel disease. J Pediatr. 2010;157:240-4.e1.
53. Frank DN. St. Amand AL, Feldman RA, et al. Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780-5.
54. Png CW, Lindén SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010;105:2420-8.
55. Pruteanu M, Hyland NP, Clarke DJ, et al. Degradation of the extracellular matrix components by bacterial-derived metalloproteases: Implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:1189-200.
56. Steck N, Hoffmann M, Sava IG, et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology. 2011;141:959-71. A demonstration that the luminal bacteria elaborate mucolytic and proteolytic enzymes, which may cause tissue damage in susceptible hosts.
57. Sibartie S, Scully P, Keohane J, et al. Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflamm Bowel Dis. 2010;16:296-304.
58. Sewell GW, Marks DJB. SegalAW. The immunopathogenesis of Crohn's disease: A three-stage model. Curr Opin Immunol. 2009;21:506-13.
59. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PLoS One. 2011;6(5):e20447. doi:10.1371/journal.pone.0020447.
60. Sears CL, Pardoll DM. Perspective: Alpha-bugs, their microbial partners and the link to colon cancer. JID. 2011;203:306-11.
61. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292-8. This and the following paper raise the possibility of a new microbial biomarker of colon cancer but cause and effect relationships have not been established.
62. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299-306.
63. Ohkusa T, Okayasu I, Ogihara T, et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003;52:79-83.
64. Swidsinski A, Dörffel Y, Loening-Baucke V, et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/ necrophorum. Gut. 2011;60:34-40.
65. Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17(9):1971-8.
66. Allen-Vercoe E, Strauss J, Chadee K. Fusobacterium nucleatum: An emerging gut pathogen? Gut Microbes. 2011 Sep 1;2(5). [Epub ahead of print].
67. Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330:831-5. An intriguing example of the microbiome as a drug target.
68. Shanahan F. Gut microbes: From bugs to drugs. Am J Gastroenterol. 2010;105:275-9.
69. Im GY, Modayil RJ, Lin CT, et al. The appendix may protect against Clostridium difficile recurrence. Clin Gastroenterol Hepatol. 2011;9:1072-7.
70. Na X, Kelly C. The vermiform appendix and recurrent Clostridium difficile infection: A curious connection. Clin Gastroenterol Hepatol. 2011;9:1017-9.
71. Guo B, Harstall C, Louie T, et al. Systematic review: Faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther. 2012;35:865-75.
72. Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(5):761-7.